Woodline Partners LP Has $6.92 Million Stock Position in Capricor Therapeutics, Inc. $CAPR

Key Points

• Woodline Partners LP increased its stake in Capricor Therapeutics by 15.8% in Q1, owning 1.60% of the company valued at approximately $6.9 million.
• Capricor's stock has experienced significant volatility, with a 1-year range between $4.20 and $23.40, and currently opened at $6.36 with a market cap of $290.78 million.
• Recent analyst ratings on Capricor Therapeutics show a mix of sentiments, with target prices ranging from $12.00 to $40.00, indicating differing expectations for the stock's future performance.

Woodline Partners LP lifted its position in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 15.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 729,318 shares of the biotechnology company's stock after purchasing an additional 99,384 shares during the quarter. Woodline Partners LP owned 1.60% of Capricor Therapeutics worth $6,921,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Octagon Capital Advisors LP bought a new position in shares of Capricor Therapeutics during the first quarter worth $4,270,000. Goldman Sachs Group Inc. boosted its position in shares of Capricor Therapeutics by 39.5% during the first quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company's stock worth $3,902,000 after purchasing an additional 116,373 shares in the last quarter. AWM Investment Company Inc. bought a new stake in Capricor Therapeutics in the 1st quarter valued at $833,000. Connective Capital Management LLC bought a new stake in Capricor Therapeutics in the 1st quarter valued at $219,000. Finally, Worth Venture Partners LLC bought a new stake in Capricor Therapeutics in the 1st quarter valued at $155,000. 21.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CAPR. HC Wainwright reaffirmed a "buy" rating and issued a $24.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, September 11th. B. Riley began coverage on shares of Capricor Therapeutics in a research report on Thursday, June 26th. They issued a "buy" rating and a $21.00 price objective on the stock. Oppenheimer cut their price objective on shares of Capricor Therapeutics from $43.00 to $22.00 and set an "outperform" rating on the stock in a research report on Monday, June 23rd. Wall Street Zen cut shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Finally, Jones Trading cut their price objective on shares of Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating on the stock in a research report on Wednesday, June 25th. One equities research analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $22.56.

Capricor Therapeutics Price Performance

NASDAQ:CAPR traded up $0.22 on Thursday, hitting $6.30. 397,107 shares of the company's stock were exchanged, compared to its average volume of 1,912,479. The firm has a 50-day moving average price of $7.13 and a 200-day moving average price of $9.67. Capricor Therapeutics, Inc. has a 52 week low of $4.92 and a 52 week high of $23.40. The company has a market cap of $288.02 million, a P/E ratio of -3.83 and a beta of 0.73.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Capricor Therapeutics had a negative return on equity of 62.71% and a negative net margin of 181.71%. On average, research analysts expect that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.